Keywords:
Stomach (incl. Oesophagus), Oncology, Nuclear medicine, PET-CT, Diagnostic procedure, Neoplasia
Authors:
L. Evangelista, A. R. Cervino, R. Alfieri, C. Castoro, P. C. Muzzio, F. Pomerri; Padova/IT
DOI:
10.1594/ecr2012/B-0657
Results
15 patients had negative and 41 positive (27 vs. 73%) FDG PET/CT after neo-adjuvant therapy.
6/15 underwent radical-intent surgery and 9/15 did not,
whereas 31/41 performed surgery and 10/41 did not (p<0.05) (Figure 1).
After a median time of 10 months,
28 patients were disease-free,
15 relapsed and 11 died.
Disease-free survival was significantly better in patients with negative than positive FDG PET/CT (83 vs.
11%; p>0.05).
Similarly,
the overall survival was significantly higher in patients with negative than with positive FDG PET/CT after neo-adjuvant treatment (80 vs. 51%; log rank p<0.05; Figure 2).
Considering patients with positive FDG PET/CT,
in non-surgery subset only 1 patient was alive without evidence of disease while in surgery subset 17 patients were disease-free (10 vs. 55%,
p<0.001; Figure 3).